Enhanced Galactosylation For Biotherapeutic Development

FUJIFILM Irvine Scientific, Inc., has introduced the BalanCD Gal Supplement. The new formula has been developed to increase galactosylation in biotherapeutic development, to help achieve desired glycan profiles for improved product quality and antibody efficacy.

Glycosylation is a critical aspect in development and optimization of protein-based therapeutics. The type and level of glycosylation can significantly affect antibody binding, function, and therapeutic efficacy. BalanCD Gal Supplement is a chemically-defined, animal component-free formula designed to increase N-linked galactosylation with a scalable protocol, offering researchers a simple method to control the process through the cell culture medium. The supplement is effective at low concentrations and is compatible with any basal growth medium.

BalanCD Gal Supplement has been developed as part of the BalanCD CHO media platform - an extended portfolio of chemically-defined, animal component-free growth and feed media formulated using Rational Culture Media Design. This multidimensional approach uses sequential, complementary development methods to leverage scientists’ knowledge of the effects of components and process parameters. The result is a media platform that delivers the precise combination of nutrients to maximize productivity, growth, and viability of CHO cell lines.